Massachusetts state legislators are considering a dangerous bill that could stifle innovation, limit patients’ access to medicines, and interfere with market competition. The bill would grant the state government broad authority to arbitrarily set the prices of medications, which could threaten the biopharmaceutical industry’s contributions to the state’s economy.
We all share the goal of ensuring that life-saving medicines are accessible and affordable for all, but this misguided bill is not the solution. Massachusetts lawmakers should reject this proposal because it could:
For the past two years, the United States government has had to deal with most major legislative and regulatory actions against the backdrop of the COVID-19 pandemic.
For the past two years, the United States government has had to deal with most major legislative and regulatory actions against the backdrop of the COVID-19 pandemic. In making policy,.